Liraglutide for weight loss: what TikTok gets wrong

What did @vsg_bestie actually say?

The creator says they just started compounded liraglutide, which they call "the compound version of Saxenda," and they're asking their followers whether it works. They describe liraglutide as "the original GLP-1 that a lot of people were placed on," note it requires a daily injection rather than weekly, and express skepticism about its effectiveness compared to tirzepatide and semaglutide. They also mention hearing about retatrutide but can't keep track of all the newer agents. There's no false miracle claim here. This is someone sharing a personal experience and asking a community question. That honesty is actually refreshing. But several of the characterizations they make deserve a closer look, because the framing around liraglutide being less effective and semaglutide being "the next best thing" is more complicated than it sounds.

Does the science back this up?

On the core effectiveness question, yes, the data does generally favor semaglutide and tirzepatide over liraglutide for weight loss, but the gap isn't as simple as "old drug bad, new drug good." The SCALE Obesity trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) showed liraglutide 3.0 mg produced about 8 percent mean body weight loss over 56 weeks. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4 mg produced roughly 14.9 percent mean weight loss. Tirzepatide in SURMOUNT-1 (Jastreboff et al., 2022, NEJM) hit up to 22.5 percent at the highest dose. So yes, there is a real efficacy gradient. But individual response varies significantly, tolerability matters, and compounded versions of these drugs are not equivalent to their brand-name counterparts in terms of regulatory oversight or verified bioavailability. That distinction is not small.

What did they get wrong (or right)?

The creator gets the daily versus weekly dosing distinction exactly right. Liraglutide is a once-daily subcutaneous injection. Semaglutide and tirzepatide are weekly. That is a real, meaningful difference in adherence burden.

Where things get murkier is the framing around compounded liraglutide as essentially equivalent to Saxenda. Saxenda is FDA-approved liraglutide at 3.0 mg. Compounded liraglutide is not FDA-approved and has not been tested for bioequivalence. The FDA has repeatedly flagged concerns about compounded GLP-1 products, including quality and dosing consistency. Calling it "the compound version of Saxenda" implies a direct equivalency that regulators explicitly do not endorse.

The characterization of semaglutide as "the next best thing" after tirzepatide is a reasonable lay interpretation of the efficacy data, but it skips over the fact that response is individual. Some people do better on liraglutide. The idea that newer always means better for a given patient is not how pharmacology works.

What should you actually know?

If you're considering any GLP-1 receptor agonist, here is what the evidence actually shows you should weigh.

• Liraglutide has the longest real-world track record of the GLP-1 agents for weight management, with cardiovascular outcome data from the LEADER trial (Marso et al., 2016, NEJM) in type 2 diabetes populations.
• Semaglutide's weight loss advantage over liraglutide is real and statistically significant, but both drugs require diet and lifestyle changes to maintain results. Neither is a standalone fix.
• Tirzepatide works on both GLP-1 and GIP receptors, which is a distinct mechanism, not just a "stronger" version of semaglutide. That matters for how it's evaluated clinically.
• Retatrutide, which the creator mentions, is still in clinical trials as of 2024. It is not FDA-approved. Hearing about it on TikTok is not the same as it being a viable clinical option right now.
• Compounded GLP-1 drugs are not the same as brand-name drugs, legally or pharmacologically. The FDA does not verify their potency, sterility, or dosing accuracy the same way it does for approved products.

Talk to a licensed provider before switching between any of these agents. The efficacy hierarchy matters less than whether a drug is appropriate, tolerable, and properly dosed for you specifically.